ROSARIO MARÍA
SÁNCHEZ MARTÍN
CATEDRÁTICA DE UNIVERSIDAD
ANA
CONEJO GARCÍA
CATEDRÁTICA DE UNIVERSIDAD
Publicaciones en las que colabora con ANA CONEJO GARCÍA (12)
2023
-
N-aryltetrahydroisoquinoline derivatives as HA-CD44 interaction inhibitors: Design, synthesis, computational studies, and antitumor effect
European Journal of Medicinal Chemistry, Vol. 258
2022
-
Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles
Pharmaceutics, Vol. 14, Núm. 4
2013
-
Antiproliferative activity, cell cycle, and apoptosis studies of a series of 6-substituted 9H-purin-9-yl-pyridinium derivatives on a human cervical carcinoma cell line
ChemMedChem, Vol. 8, Núm. 8, pp. 1266-1269
2007
-
QSAR as a tool for the development of potent antiproliferative agents by inhibition of choline kinase
Current Computer-Aided Drug Design, Vol. 3, Núm. 4, pp. 297-313
2006
-
(Q)SAR studies to design new human choline kinase inhibitors as antiproliferative drugs
Current Medicinal Chemistry, Vol. 13, Núm. 11, pp. 1231-1248
2005
-
1H and 13C spectral assignment of symmetrical bis[(4-aminosubstituted)quinolinium] derivatives
Magnetic Resonance in Chemistry, Vol. 43, Núm. 12, pp. 1066-1071
-
Symmetrical bis-quinolinium compounds: New human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line
Journal of Medicinal Chemistry, Vol. 48, Núm. 9, pp. 3354-3363
-
Towards a model for the inhibition of choline kinase by a new type of inhibitor
European Journal of Medicinal Chemistry, Vol. 40, Núm. 3, pp. 315-319
2004
-
Influence of the linker in bispyridium compounds on the inhibition of human choline kinase
Journal of Medicinal Chemistry, Vol. 47, Núm. 22, pp. 5433-5440
2003
-
Bispyridinium cyclophanes: Novel templates for human choline kinase inhibitors
Journal of Medicinal Chemistry, Vol. 46, Núm. 17, pp. 3754-3757
-
Conformational Dynamics of a Bispyridinium Cyclophane
Journal of Organic Chemistry, Vol. 68, Núm. 22, pp. 8697-8699
-
QSAR-derived Choline Kinase inhibitors: How rational can antiproliferative drug design be?
Current Medicinal Chemistry, Vol. 10, Núm. 13, pp. 1095-1112